Advanced Search

 

Study ID Status Title Patient Level Data
S3BA2001 Completed A 12-week, Dose-ranging, Double-blind, Placebo-controlled Study of Alosetron (GR68755) in Subjects with Irritable Bowel Syndrome
S3BA2002 Completed Characterization of Changes in Regional Brain Activity Associated With Sigmoid Sensitization in IBS Patients Using Positron Emission Tomography (PET) With and Without Alosetron Therapy
S3BA3001 Completed A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Alosetron (GR68755) in Female Subjects With Irritable Bowel Syndrome
S3BA3002 Completed A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Alosetron (GR68755) in Female Subjects With Irritable Bowel Syndrome
S3BA3003 Completed A 12-Month Randomized, Double-blind, Placebo-controlled Study to Evaluate the Quality of Life and Safety Associated with the Long-term Use of Alosetron (GR68755) in Subjects with Irritable Bowel Syndrome (Final Analysis)
S3BB1002 Completed A Study to Investigate the Effect of Alosetron (4mg), BID for 7½ Days, on 24-Hour Small Bowel Motility, in Patients With Irritable Bowel Syndrome (IBS)
S3BB1004 Completed A study to determine the effects of food on the pharmacokinetics of oral alosetron in healthy volunteers.
S3BB1010 Completed Report of a study to compare the pharmacokinetics of, and tolerability to, a single, oral, 1 mg dose of alosetron in healthy subjects and subjects with renal impairment not requiring dialysis.
S3BB1011 Completed The pharmacokinetics of alosetron 1 mg bid oral administration for 29 days in healthy subjects.
S3BB2009 Completed A Double-Blind Placebo-Controlled Study to Determine the Efficacy of GR68755C (Alosetron) in Treatment of Irritable Bowel Syndrome
S3BB2011 Completed A study to investigate the effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome (IBS).
S3BB3001 Completed A Multicentre, Randomised, Double-blind Comparison of Alosetron 1mg bd against Mebeverine 135mg tds for 12 Weeks in the Treatment of Female Patients with Irritable Bowel Syndrome
S3BB3002 Completed A Multicentre, Randomised, Double-Blind Comparison of Alosetron 1mg bd against Trimebutine 200mg tds for 12 weeks in the Treatment of Female Patients with Irritable Bowel Syndrome.
S3GK01 Completed A Study to Determine the Pharmacokinetics of Orally Administered Ondansetron 16mg in Patients Having Surgery Under General Anaesthesia
S6491365 Completed A Single Dose Bioequivalence Study of 2 different doses of Mini Cherry Nicotine Lozenges
S7120994 Completed Evaluation of the nicotine lozenge in relief of provoked acute craving
S7121359 Completed Evaluation of the Nicotine Mini Lozenge in Relief of Provoked Acute Craving
SALMD/AH90/J85 Completed A phase IV, multi-centre, double-blind, double-dummy, parallel group study to determine whether adult asthmatic patients, currently symptomatic on 400mcg daily inhaled corticosteroid therapy, are better maintained by an increase in corticosteroid dose to 1000mcg daily beclomethasone dipropionate ...
SALMP/AH91/D89 Completed A phase III, multi-centre, double-blind, placebo controlled, parallel group study assessing the efficacy and safety of inhaled salmeterol xinafoate (Serevent™) 50 micrograms BD via the Diskhaler™ when added to the existing treatment of moderate to severe asthmatic children.
SALMP/AH93/J119 Completed A phase IV, multi-centre, double-blind, randomised, parallel group study in general practice to compare the efficacy and tolerability of inhaled salmeterol xinafoate 50 micrograms bd with placebo, both administered via the Diskhaler, in the treatment of episodic asthma induced by upper respirato ...
SAM 106538 Completed Asthma control assessment via ACT and DRC in Asthmatics treated with Seretide (50/250) over 12 weeks
SAM101667 Completed A multicentre, randomised, double-blind, parallel group study to compare the efficacy and safety of Salmeterol/Fluticasone propionate combination product (Seretide®) 50/100 mcg with Fluticasone propionate (Flixotide® ) 200 mcg, both delivered twice daily via the DISKUS inhaler, in the treatment of children aged 6-12 years with symptomatic asthma
SAM103848 Completed Randomised, double-blind, double-dummy, parallel-group, comparative study of salmeterol/FP 50/100mcg bd inhalation powder via Diskus with oral Montelukast (5mg QD) chewable tablets in Children 6-14 years
SAM104926 Completed A multicentre, randomised, double-blind, double dummy, parallel group study to compare the salmeterol/fluticasone propionate combination (SeretideTM) at a dose of 50/100µg twice daily and fluticasone propionate (FlixotideTM) at a dose of 200µg twice daily, both delivered via a dry powder inhaler (DiskusTM) for 12 weeks in asthma in children aged 4-11 years not controlled by inhaled corticosteroids alone at medium dose
SAM108037 Terminated Seretide 100 DK vs Flixotide 100 DK in IMT in moderate asthma in adults on static lung volumes (mechanistic study)

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.